Drug Trial Radar · NCT06906367
A Study of Patients With Fabry Disease (US Specific)
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Feb 13, 2026
Primary completion
Jun 2032
Study completion Jun 2032
Sponsor
- Lead sponsor
- Amicus TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 2, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an observational study to evaluate the effects of treatment on long-term effectiveness, safety, and health-related quality of life (HRQOL) in patients with Fabry disease, with a main focus on migalastat.
Conditions
- Fabry Disease
Interventions
migalastat HClDrug
Non-interventional study of participants receiving migalastat HCl 150 mg
ERTDrug
Non-interventional study of participants receiving enzyme replacement therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized rate of change in Estimated Glomerular Filtration Rate (eGFR)Time frame: Baseline and prospective up to 5 years
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
UAB Nephrology Research Clinic at Paula Building
Birmingham, Alabama · Recruiting
Arkansas Children's Hospital
Little Rock, Arkansas · Recruiting
Emory Genetics
Atlanta, Georgia · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
New York-Presbyterian Morgan Stanley Children's Hospital - Columbia University Medical Center
New York, New York · Not yet recruiting
UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania · Recruiting
Renal Disease Research Institute
Dallas, Texas · Recruiting
Lysosomal and Rare Disorders Research and Treatment Center, Inc.
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.